@article {Brown419, author = {Stephen W. Brown and Majid Mehtali}, title = {The Avian EB66{\textregistered} Cell Line, Application to Vaccines, and Therapeutic Protein Production}, volume = {64}, number = {5}, pages = {419--425}, year = {2010}, publisher = {Parenteral Drug Association (PDA)}, abstract = {Embryonated chicken eggs and primary chicken embryo fibroblasts (CEFs) have been used for decades as a means of manufacturing human and veterinary vaccines. However, these egg and CEF-based production systems are associated with many serious limitations in terms of their regulatory acceptability, production capacity, and supply chain risks. The development of a safer, cheaper, and more efficient cell substrate for vaccine production would represent a significant business advantage for vaccine manufacturers. Building on the exceptional properties of avian embryonic stem cells, Vivalis has created a new cell substrate, the Duck EB66{\textregistered} cell line. This article describes how this cell substrate was derived, the manufacture and qualification of a master cell bank, and the evaluation of the cell substrate for the manufacture of vaccines and human therapeutic proteins.}, issn = {0006-3363}, URL = {https://journal.pda.org/content/64/5/419}, eprint = {https://journal.pda.org/content/64/5/419.full.pdf}, journal = {PDA Journal of Pharmaceutical Science and Technology} }